Agilent (A) Q3 2026 Earnings Call Transcript

Agilent reported Q3 revenue of $1.88B (+8.1% reported / +7.3% core), beating the high end of guidance by 140bps, with non-GAAP EPS of $1.56 (+$0.06 above the top of guidance). Full-year FY26 revenue guidance was raised to $7.49B–$7.51B (core growth 5.8%–6.0%) and non-GAAP EPS to $6.18–$6.21, while Q4 revenue is guided at $1.98B–$2.0B and free cash flow was $439M (96% conversion). Strategic pricing under the Ignite Operating System contributed ~200bps to the quarter, and management cited strong growth in Pharma (+12%) and Advanced Therapeutics CDMO (+~30%), plus a China step-up (+9%), despite ongoing cost pressures from geopolitical/memory-chip demand and tariff refund dynamics.

Analysis

This reads less like a cyclical snapback and more like a self-help re-rating: mix is shifting toward recurring consumables/service and higher-margin specialized workflows, so the earnings revision is cleaner than the headline growth rate implies. The key second-order effect is that Agilent is using instruments as the wedge and then monetizing the installed base later; that favors ACG and service economics over pure instrument peers, and should pressure competitors that rely more heavily on upfront system sales.

The next 1-3 months matter more for order conversion than for the quarter just reported. The stock should keep reacting to whether China and reshoring can sustain above-run-rate demand into Q4, and whether the company can convert the current backlog into visible FY27 revenue without margin dilution from Train C ramp costs. Falsifiers: book-to-bill slipping below 1, China reverting to low-single-digit growth, or ex-tariff margin expansion falling back below ~100 bps as input inflation persists.

Contrarian view: the market may be underpricing the durability of pricing/operating leverage, but bulls may be overpricing the near-term CDMO contribution. Train C is a 2027-2028 story, not a clean 2026 earnings driver, and the more important debate is whether Agilent has structurally improved its share position versus TMO/WAT/BRKR. For now, the risk/reward still looks favorable, but this is a "buy the pullback" rather than chase-the-gap setup.

Key Decisions for Investors

• Go long A on any post-earnings weakness over the next 3-5 trading days; target a 6-10% move as estimate revisions catch up, with a stop if management commentary on Q4 orders or China softens materially.
• Pair trade: long A / short WAT for 1-3 months. A has better self-help, pricing, and installed-base monetization; WAT is more dependent on a cleaner macro capex rebound. Falsify if WAT re-accelerates orders or A's book-to-bill drops below 1.
• For options, buy A 3-6 month call spreads on a pullback rather than chasing spot. The trade works if the market starts capitalizing FY27 reshoring/Train C visibility before actual revenue hits.
• Watch for a 4Q order inflection and China guide commentary as the next catalyst. If China slips back toward flat or the reshoring pipeline fails to convert by year-end, cut exposure.